[1] Wolfson JS,Swartz MN.Drug therapy. Serum bactericidal activity as a monitor of antibiotic therapy[J].New Engl J Med,1985,312(15) :968-973.
[2] 王 睿.临床抗感染药物治疗学[M].北京:人民卫生出版社,2006:162-163.
[3] 崔邦铨,周 宗.微量血清杀菌活性测定的临床应用[J].中国冶金工业医学杂志,2002,19(1):60.
[4] 洪慧丰,李安华.微量法测定血清杀菌效价的临床应用[J].中国药师,2003,6(8):483-485.
[5] 文爱东.抗菌药物规范化及个体化应用指南[M].北京:人民军医出版社,2012:194.
[6] 叶应妩,王毓三,申子瑜,等.全国临床检验操作规程[M].第3版.南京:东南大学出版社,2006:897.
[7] Hyatt JM,Nix DE,Schentag JJ.Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae , Staphylococcus aureus , and Pseudomonas aeruginosa for which MICs are similar[J]. Antimicrob Agents Chemother, 1994,38(12):2730-2737.
[8] National Committee for Clinical Laboratory Standards. Methods for determining bactericidal activity of antimicrobial agents[S]. M21-A, NCCLS, 1999.
[9] Shaw JP, Seroogy J, Kaniga K, et al.Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects[J].Antimicrobial Agents Chemother, 2005,49(1):195-201.
[10] Hart D, Weinstein MP.Cross-over assessment of serum bactericidal activity of moxifloxacin and levofloxacin versus penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae in healthy volunteers[J]. Diagn Microbiol Infect Dis,2007,58(3):375-378.
[11] 杨延停,陈汝贤,许鸿章,等.Sansanmycin A对铜绿假单胞菌体内外抗菌活性的初步研究[J].中国抗生素杂志,2012,37(3):196-201.
[12] 白 艳,王 瑾,蔡 芸,等.头孢噻利不同剂量单次静滴在中国健康人群的血清杀菌活性[J].中国临床药理学杂志,2013,29(3):192-195.
[13] 伏 晓,代大顺,焦伟杰.应用抗菌药物继发真菌感染临床分析[J].中华医院感染学杂志,2013,23(14):3501-3503.
[14] 汪 复,张婴元.抗菌药物临床应用指南[M].第2版.北京:人民卫生出版社,2012:38-54.
[15] 周家军,董盈盈,梁蓓蓓,等.抗菌药物血清杀菌活性研究的临床意义[J].中国临床药理学杂志,2010,26(11):877-880.
[16] 白 艳,王 瑾,梁蓓蓓,等.头孢拉宗钠不同剂量单次静滴后在健康人血清的杀菌活性[J].中国临床药理学杂志,2011,27(11):822-826. |